Annual Report on the Status of Postmarketing Requirements (PMRs) and Postmarketing Commitments (PMCs) for FY2017 now available – Drug Information update

Today the Food and Drug Administration released the Annual Report on the Status of Postmarketing Requirements (PMRs) and Postmarketing Commitments (PMCs) for FY2017.   FDA is pleased to report that the majority of the PMRs/PMCs in the FY2017 report were successfully completed (fulfilled) or are progressing toward completion according to the original schedule; very few PMRs/PMCs are considered ‘delayed.’ Additionally, the FY2017 Report to Congress on the Backlog of PMRs/PMCs shows that progress continues to be made in closing out PMRs/PMCs in the "backlog.” The FDA is committed to ensuring that postmarketing requirements (PMRs) and postmarketing commitments (PMCs), which further describe the safety, efficacy, and/or optimal use of a drug, are conducted and reported as required.  For more information, please visit: FY2017 Report on PMRs/PMCs